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Despite current advances in liver transplant surgery, post-operative early allograft dysfunc-
tion still complicates the patient prognosis and graft survival. The transition from the donor
has not been yet fully understood, and no study quantifies if and how the liver function
changes through its transfer to the recipient. The indocyanine green dye plasma disappear-
ance rate (ICG-PDR) is a simple validated tool of liver function assessment. The variation
rate between the donor and recipient ICG-PDR still needs to be investigated.
Materials and methods
Single-center retrospective study. ICG-PDR determinations were performed before graft
retrieval (T1) and 24 hours after transplant (T2). The ICG-PDR relative variation rate
between T1 and T2 was calculated to assess the graft function and suffering/recovering.
Matched data were compared with the MEAF model of graft dysfunction.
Objective
To investigate whether the variation rate between the donor ICG-PDR value and the recipi-
ent ICG-PDR measurement on first postoperative day (POD1) can be associated with the
MEAF score.
Results
36 ICG-PDR measurements between 18 donors and 18 graft recipients were performed.
The mean donor ICG-PDR was 22.64 (SD 6.35), and the mean receiver’s ICG-PDR on 1st
POD was 17.68 (SD 6.60), with a mean MEAF value of 4.51 (SD 1.23). Pearson’s test
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stressed a good, linear inverse correlation between the ICG-PDR relative variation and the
MEAF values, correlation coefficient -0.580 (p = 0.012).
Conclusion
The direct correlation between the donor to recipient ICG-PDR variation rate and MEAF
was found. Measurements at T1 and T2 showed an up- or downtrend of the graft perfor-
mance that reflect the MEAF values.
Introduction
Despite 40 years of experience in the field, OLTx represents a challenging surgery and less
than complication-free. With the translation of the graft from the donor to the recipient, the
transplantation process represents a susceptible moment to numerous insults that can damage
the organ with important repercussions on the graft and patient survival [1, 2]. In the immedi-
ate postoperative period, the graft dysfunction can become a serious complication [3, 4]. The
prompt recognition of this condition is crucial to improve patient survival [5]. The Model of
Early Allograft Function (MEAF) grades the severity of liver graft dysfunction by a continuous
score, based on bilirubin, international normalized ratio, and alanine aminotransferase within
three days post-transplant, and it is a prognostic tool for 3, 6 and 12-month patient and graft
survival [6, 7]. Indocyanine green (ICG) is a cyanine dye safely used in medical diagnostics;
although with different techniques, ICG boasts broad applications from vascular and lym-
phatic perfusion assessments in the fields of gastrointestinal surgery and gynecology, to the
vascular and organ functional assessment in hepatology [8–10].
Assessment of the indocyanine green dye plasma disappearance rate (ICG-PDR) is a non-
invasive technique that could be adopted as a point-of-care test (POCT) to evaluate the liver
graft dysfunction bedside. The preliminary assessment of the graft functionality is essential to
define its suitability for transplant. Traditionally, this judgement occurs through the evaluation
of liver function tests and liver biopsy before or during organ retrieval [11].
Studies reported different ICG-PDR cut-off values in the recipient to have a prognostic role
for graft dysfunction after OLTx [5, 12–14]. Clinical interest in this technology has varied
greatly over the last twenty years, depending largely on the beliefs of the various transplant
centres, and this exposes patient outcome to Bayesian probability, shifting it into a "zone of
uncertainty" [15, 16]. Recently, some authors have demonstrated the similar predictive role of
the ICG-PDR performed on the liver donor compared to early allograft dysfunction (EAD),
without testing the assay on the recipient [17].
The transition from the donor to the recipient has not been yet fully understood, and no
study quantifies how and if the liver function changes in its transfer to the recipient by apply-
ing the assay to study this transition. The hypothesis of our study is to analyze whether the var-
iation rate between the donor ICG-PDR value and the recipient ICG-PDR measurement in




This was a single center retrospective study analyzing the ICG-PDR variation rate between
liver transplant donors immediately before harvesting and recipients at post-operative day 1
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(POD1). All organs were sourced from donors after brain death (DBD) hospitalized in the
Intensive Care Unit of the University Hospital of Udine. The informed consent for the dona-
tion of organs was obtained with respect to the Italian law, art. 91/99 and 578/93. All transplan-
tation procedures were performed at the University Hospital of Udine from October 2019 to
December 2020. The study was conducted following the ethical principles deriving from the
Declaration of Helsinki and was approved by our Institutional Review Board number 021/
2021. None of the transplant donors was from a vulnerable population. The patient’s willing to
participate in clinical studies was obtained through the general consent (GECO) system, and
the European General Data Protection Regulation 2016/679 was (GDPR) respected. A general
informed consent for research purposes was signed by all admitted patients and the same stan-
dard-of-care was applied.
Study population
All liver grafts were harvested from donors after brain death (DBD). Only elective patients
with end-stage liver disease scheduled through the Model for End-stage Liver Disease (MELD)
score were enrolled in this study. The inclusion criteria were: (a) ICG-PDR testing performed
on the donor just before liver procurement and (b) ICG-PDR testing performed on the first
postoperative day (POD) on respective graft recipients. Exclusion criteria were: intra-operative
mortality, acute vascular complications, active bleeding in the immediate postoperative period
(24 hours) and known iodine allergy. The peri- and postoperative collected data included
details regarding donor’s and recipient’s ICG-PDR values, demographical data, graft charac-
teristics, blood transfusion requirements during surgery and blood chemistry in the first seven
days after OLTx.
Study protocol
ICG-PDR determinations were tested in the intensive care unit before entering the operating
room for graft retrieval (T1) and 24 hours after OLTx surgery (T2). ICG-PDR was assessed by
pulse spectrophotometry to provide a real-time picture of a transplanted graft’s metabolic
function before and after surgery. A detailed explanation of ICG-PDR measurement is
reported in our previous publication [18]. To estimate the graft function and recovering/suf-
fering ICG-PDR relative variation rate between T1 and T2 was calculated. These data were
subsequently matched and analyzed with graft dysfunction described as MEAF. According to
the literature, the MEAF score was assessed for each recipient considering the highest INR,
ALT and total bilirubin within the first three postoperative days:
MEAF = (score ALTmax3POD + score INRmax3POD + score bilirubin3POD)
score ALTmax3POD = 3.29 / [1 + e
-1.9132 (ln (ALTmax3POD)– 6.1723)]
score INRmax3POD = 3.29 / [1 + e
-6.8204 (ln (INRmax3POD)– 0.6658)]
score bilirubin3POD = 3.4 / [1 + e
-1.8005 (ln (bilirubin3POD)– 1.0607)]
The MEAF Scoring System provides a significant association with patient survival for the 3-
, 6-, and 12-month follow-up, including that the higher the MEAF Score is, the lower the recip-
ients’ and grafts’ survival rates are [6].
All patients were considered with a minimum follow-up of 90 days. The ICG-PDR log-vari-
ation rate was associated with a new composite endpoint called Hospital-Free Days (HFD).
HFD summarizes the postoperative outcomes into the number of days patients spend outside
of any healthcare facility in an observation period of 90 days after OLTx. ICG-PDR testing on
liver transplant recipients has been a standard-of-care for 20 years at our institution. From
2019, ICG-PDR testing has been implemented as standard-of-care for all (DBD) liver donors
and transplant recipients. Since the feasibility of performing ICG-PDR tests in the donor
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before entering the operating room for graft retrieval may not be equally accepted worldwide,
ethical and legal regulations from each country may limit the applicability of the findings from
this study.
Outcome measures
The primary study outcome was to evaluate the association between the distribution of the rel-
ative variation of the ICG-PDR values before and after surgery (T1 and T2) and the MEAF
score.
Statistical analysis
Considering the results of the Shapiro-Wilk test for normality, quantitative variables were pre-
sented as means and standard or median deviations plus the range. Qualitative variables are
expressed as absolute and relative frequencies. We assessed the distribution of the relative vari-
ation in ICG-PDR values [(logICG-PDR2 –logICG-PDR1)/ICG-PDR1] at the two different
time points (T1 before explant, and T2 at the first post-OLTx day). We applied Pearson’s test
to assess for statistically significant correlation with MEAF. Subsequently, the linear regression
analysis was performed. We tested via ANOVA the presence of any association between
MEAF and dichotomic variables or via correlation test if the analyzed variable was continuous.
The association between qualitative variables was tested using the χ2 chi-square test and Fish-
er’s exact test. Statistical significance was considered for p-values�0.05. MedCalc Statistical
Software version 16.4.3 (MedCalc Software bv, Ostend, Belgium; 2016) from the text box into
the manuscript was used.
Results
During the study period 36 ICG-PDR measurements between 18 donors and 18 graft recipi-
ents were performed. Demographical, clinical and patient history data are shown in Tables 1
and 2. The mean age of donors and recipients was 51.5 and 56.3 years, respectively (SD 16.25
and 10.48), mean DRI was 1.46 (SD 0.34), mean recipient BMI was 24.36 (SD 3.12), mean
MELD-Score was 12.5 (IQE 10.0–17.0). The mean donor ICG-PDR was 22.64 (SD 6.35), and
the mean receiver’s ICG-PDR on 1st POD was 17.68 (SD 6.60), mean MEAF value was 4.51
(SD 1.23), Table 3. ICG-PDR values show a tendency to decrease between time zero (T1) and
24 h post-OLTx (T2) in the cohort of patients who presented with higher MEAF values. The
assessment of the distribution of the relative variation in ICG-PDR was calculated at two
times, as mentioned above. We applied Pearson’s test that underlined a good, linear inverse
correlation between the relative variation of the ICG-PDR and the MEAF values with a corre-
lation coefficient of -0.580 (p = 0.012). Figs 1 and 2; Table 4. Linear regression analysis discov-
ered an R2 value of 0.336. HFD after OLTx, showed a mean value of 64.78 (SD 6.71) days. A
mean of 68.67 (SD 6.56) days was notable for patients showing a positive up-trending log
ICG-PDR variation rate, vs 62.83 (SD 6.13) days within the transplants showing a negative
ICG-PDR variation rate, although without reaching statistical significance. The ICG-PDR
value at T2 stressed the correlation with MEAF, (p = 0.002). No deaths, no PNF and no re-
transplants were observed in a 90-day follow-up period.
Discussion
The main findings of our study are as follows: first, we found an association between the varia-
tion rate of the donor-recipient ICG-PDR and MEAF; secondly, we found that the ICG-PDR
on the first postoperative day was related with MEAF. The organ transition from the donor to
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Table 2. Recipient demographical and laboratory data.
Total number of Patients 18
Age, years (mean, SD) 56.28 (10.48)
Male/Female 11 / 7
BMI kg/m2 (mean, SD) 24.36 (3.12)
MELD score, n (median, IQR) 12.5 (10–17)
LOS, days (median, IQR) 20 (17–26)
Biochemical values on 1st PO day
SOFA score on 1st PO, n (median, IQR) 7 (6–7)
Lactates on 1st POD, mEq/L (mean, SD) 1.11 (0.48)
Bilirubin on 1st POD, mg/dL (median, IQR) 3.05 (1.81–6.97)
ALT on 1st PO, IU (median, IQR) 695.5 (502.0–1205.0)
AST on 1st PO, IU (median, IQR) 809.5 (465.0–1951.0)
Creatinine, mg/dL (mean, SD) 1.35 (0.57)
INR, % (mean, SD) 1.47 (0.20)
Graft characteristics on 1st PO day
ICG-PDR, %/min T2 (mean, SD) 17.68 (6.60)
BMI, Body Mass Index; MELD, Model for End-stage Liver Disease; IU, International Units; SOFA score, Sequential
Organ Failure Assessment score; ALT, Alanine AminoTransferase; AST, Aspartate Amino-Transferase; INR,
International Normalized Ratio; ICG-PDR, IndoCyanine Green dye Plasma Disappearance Rate; IQR, Interquartile
Range; SD, Standard Deviation; n, number; min, minutes; 1st POD, first Post-Operative Day
https://doi.org/10.1371/journal.pone.0256786.t002
Table 1. Donor demographical and laboratory data.
Total number of patients 18
Age, years (mean, SD) 51.50 (16.25)
Male/Female 10 / 8
BMI kg/m2 (mean, SD) 26.38 (5.27)
Biochemical values
Lactates, mEq/L (mean, SD) 1.07 (0.90–1.21)
Bilirubin, mg/dL (mean, SD) 2.48 (0.99)
ALT, IU (mean, SD) 61.37 (8.22)
AST, IU (mean, SD) 56.05 (8.40)
AP, IU (mean, SD) 55.39 (38.57)
GGT, IU (median, IQR) 23.5 (14.0–33.0)
Creatinine, mg/dL (mean, SD) 1.06 (0.38)
INR, % (median, IQR) 1.08 (1.02–1.27)
Sodium, mEq/L (mean, SD) 150.94 (9.37)
Graft characteristics
ICG-PDR, %/min T1 (mean, SD) 22.64 (6.35)
Steatosis, % (mean, SD) 12 (8.93)
Donor Risk Index, n (mean, SD) 1.46 (0.34)
Cold Ischemia time, min (mean, SD) 372.89 (91.36)
Warm Ischemia time, min (median, IQR) 35 (30–40)
Cause of Death
Traumatic head injury, n (%) 5 (27.8)
Haemorrhagic stroke, n (%) 13 (72.3)
BMI, Body Mass Index; ALT, Alanine AminoTransferase; AST, Aspartate Amino-Transferase; AP, Alkaline
Phosphatase; GGT, gamma-glutamyl transferase; INR, International Normalized Ratio; ICG-PDR, IndoCyanine
Green dye Plasma Disappearance Rate; IQR, Interquartile Range; SD, Standard Deviation; n, number; min, minutes
https://doi.org/10.1371/journal.pone.0256786.t001
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the recipient is very sensitive to several insults that can lead to the impaired postoperative
functional recovery of the graft. Liver transplantation represents the final stage of a complex
multi-phase procedure consisting of organ procurement, preservation, preparation, and
implantation. Ischemia-reperfusion damage (IRI), the quality of the donor graft, and the recip-
ient’s condition at the time of transplantation can be the main factors responsible for the onset
of graft dysfunction [19]. The overall quality of the graft depends on the donor’s age, the
degree of steatosis (assessed by liver biopsy) or the use of marginal donor organs from
"Extended criteria donors" (ECD). Given the growing demand for organs, grafts from ECD
Table 3. Outcomes.
Outcomes
MEAF (mean, SD) 4.51 (1.23)
HFD, days (mean, SD) 64.78 (6.71)
HFD [in positive logICG-PDR var rate (mean, SD)], days (mean, SD) 68.67 (6.56)
HFD [in negative logICG_-PDR var rate (mean, SD)], days (mean, SD) 62.83 (6.13)
ICG-PDR variation rate (mean, SD) -0.0048 (0.0089)
PNF, n (%) 0 (0)
Re-OLTx, n (%) 0 (0)
Deaths [90 –day mortality], n (%) 0 (0)
MEAF, Model for Early Allograft Function; HFD, Hospital-Free Days; ICG-PDR variation rate, IndoCyanine Green
dye Plasma Disappearance Rate variation rate calculated as follows [(logICG-PDRt2 –logICG-PDRt1)/ICG-PDRt1];
PNF, Primary Non-Function; Re-OLTx, Re–transplantation; IQR, Interquartile Range; SD, Standard Deviation; n,
number; min, minutes; 1st PO, first Post-Operative Day.
https://doi.org/10.1371/journal.pone.0256786.t003
Fig 1. Estimation plot for paired ICG-PDR samples.
https://doi.org/10.1371/journal.pone.0256786.g001
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constitute an indispensable resource. The prompt recognition of the donor liver function is of
paramount importance to predict the postoperative liver-graft function and to improve the
patient survival. The MEAF score, as literature reports, should be considered the gold standard
to predict and detect the occurrence of graft dysfunction, with its intrinsic limitations as either
moderately “good” or moderately “bad” [7].
Fig 2. Scattered comparison graph.
https://doi.org/10.1371/journal.pone.0256786.g002
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Over the last decades, indocyanine green plasma disappearance rate (ICG-PDR) aroused
modest interest between researchers and clinicians as a tool of liver function assessment.
Numerous studies about the efficacy of the ICG-PDR testing performed on the first postopera-
tive day to predict the graft performance and early outcome after OLTx have been published
[20, 21]. Some authors observed an association between low ICG-PDR values and the onset of
EAD after transplantation with a decrease in overall survival [5]. From our previous study
based on a cohort of 78 patients, the ICG-PDR on the 1st PO day represents an easy, repeat-
able, and bedside measurement able to predict EAD and graft survival at 1- and 5-years with a
cut-off value of 16%/min [18]. Other authors observed that low ICG-PDR values,
respectively < 12.85 and < 9.6%/min, were associated with early post-operative complications
and death [5, 13, 22]. In 2014, Klinzing et al. observed that the combination of a high recipient
MELD score (MELD >25) and a low ICG-PDR measured in the early postoperative phase
(ICG-PDR < 20%/minute) was significantly related to longer supportive intensive care stay
and hospitalization for liver transplant recipients [23].
Few studies have focused their attention on testing ICG-PDR on liver donors. Koneru et al.
(1994) pioneered the ICG-PDR for the quality assessment of the graft. The authors showed
that an ICG-PDR value lower than 15%/min was an objective evaluation to predict transplant
Table 4. Association between variables and the distribution of the relative variation in ICG-PDR.
Distribution of the relative variation in ICG-PDR, significance level expressed as p-
value
Age of recipient p-value = 0.357
BMI recipient p-value = 0.853
Cold ischemia time p-value = 0.236
Warm ischemia time p-value = 0.161
UEC p-value = 0.792
Plasma p-value = 0.235
MEAF p-value = 0.012
Lactates on 1st POD p-value = 0.378
AST on 1st PO p-value = 0.272
ALT on 1st PO p-value = 0.376
Serum albumin on 1 st
POD
p-value = 0.016
GGT on 1 st POD p-value = 0.143
HFD p-value = 0.079
Age of donor p-value = 0.103
BMI donor p-value = 0.957
Steatosis p-value = 0.617
Donor risk index p-value = 0.141
Lactates of donor p-value = 0.102
AST of donor p-value = 0.305
ALT of donor p-value = 0.414
GGT of donor p-value = 0.017
MELD p-value = 0.104
MELD, Model for End-stage Liver Disease; ICG-PDR, IndoCyanine Green dye Plasma Disappearance Rate; UEC N˚,
Number of Units of packed red blood cells; ALT, Alanine AminoTransferase; AST, Aspartate Amino-Transferase;
GGT, Gamma Glutammil-Tranferase: IQR, Interquartile Range; HFD, Hospital Free Days; MEAF, Model for Early
Allograft Dysfunction.
https://doi.org/10.1371/journal.pone.0256786.t004
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graft quality [24]. Vos et al. (2014) studied the ICG-PDR to assess graft suitability from cadav-
eric donors before the organ retrieval. The authors found the ICG-PDR value <15%/min dur-
ing the donor observation period to be associated with a poor outcome of the graft after
transplantation [25]. Zarrinpar et al. (2015) considered the ICG-PDR testing to assess donors
after brain death (DBD) and observed a relationship with graft survival [26]. In 2017, Tang
et al. confirmed that the ICG-PDR testing in donors after brain death could be an effective
quantitative method to predict functional graft recovery and improve early graft prognosis
after liver transplantation [27]. These findings suggest that poor quality grafts are more sensi-
tive to ischemia-reperfusion injury than the group with a lower donor risk index (DRI). More
recently, in 2020, JM Asencio et al. studied the ICG-PDR from DBD donors to predict graft
rejection in the recipients [28].
The low cost of the indocyanine green test, its simplicity, and the short time it took to per-
form it on both donors and recipients made it a valid tool to assess the progressive status of the
graft function before and after transplantation.
In our study, we analyzed the difference between two measurements of ICG-PDR for the
same graft before and after liver transplantation. We calculated the variation rate in ICG-PDR
(ICG-PDR-rate) as an expression of graft damage, and we found that the variation is directly
correlated with the Model of Early Allograft Function (MEAF). To our knowledge, before this
study, there was no research in the literature investigating the ICG-PDR in both donor and
recipient livers.
The calculated ICG-PDR variation rate is a dynamic index that assesses over time the evolu-
tion of the liver metabolic balance from the donor to the recipient and opens the way to
numerous in-depth studies.
From our analysis, we noted that in two thirds of the cohort the ICG-PDR variation rate
decreased, suggesting a worsening in the graft-liver function. Higher MEAF scores among
these patients also coherently explained the trend. Interestingly, the ICG-PDR variation rate
increased between the rest of the population which was also notable for lower MEAF scores.
ICG-PDR measurement performed at T1 (donor) and T2 (recipient) showed an up- or down-
trend of the graft performance, able to reflect the MEAF values. Additional data from the
donor, such as, graft steatosis, warm and cold ischemia times, did not correlate with MEAF in
our case series. This finding can probably rely on the condition of the donor himself.
The hypothesis that ICG-PDR variation rate could represent a measure of the ischemia and
reperfusion injury (IRI) as previously hinted by Plevris et al seems to be supported by the
results of our study showing good correlation between ICG-PDR values from donors to recipi-
ents and MEAF scores post-transplant [29].
The intention of photographing the liver function in two different moments of the trans-
plant process, revealed an interesting finding. If we look at the daily practice, it is arguable to
assess the graft performance simply and objectively after OLTx. The ICG-PDR variation rate
can be seen as a simple tool to appraise the early outcomes and could open an interesting win-
dow for the application of this technique to in the daily routine of the transplant surgeons. In
fact, ICG-PDR is a simple and cost-effective tool, simple to read and above all simple to
compare.
Furthermore, this is a pilot-study and some limitations also need to be acknowledged: we
reviewed our database retrospectively. We did not perform any power analysis about the
study’s primary aim but only analyzed the available data. In patients with low cardiac output
or massive active bleeding the ICG-PDR may not provide reliable information, therefore
ICG-PDR was performed only in the case of hemodynamic stability. Moreover, the small
cohort of patients did not allow us to investigate certain aspects in depth. It would be interest-
ing to deepen the current knowledge about the increase/decrease in donor-recipient PDR
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observed in some cases. Certainly, by expanding the sample size, it will be possible to increase
the variety of procured grafts and investigate the role of the PDR rate in such contexts.
Conclusions
In conclusion, we found a direct correlation in ICG-PDR variation rate from donor-recipient
and MEAF. ICG-PDR variation rate is an easy, bedside, repeatable measurement to estimate
graft perioperative liver graft dysfunction. Further studies are needed to confirm our results in
a large population and between centers. That will make it possible in the future to outline
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Plasma Disappearance Rate Indocyanine Green Clearance as a Predictor of Liver Graft Rejection in
Donor Brain Death. Transplant Proc. 2020; 52(5):1472–1476. https://doi.org/10.1016/j.transproceed.
2020.01.084 PMID: 32217011
29. Plevris JN, Jalan R, Bzeizi KI, Dollinger MM, Lee A, Garden OJ, et al. Indocyanine green clearance
reflects reperfusion injury following liver transplantation and is an early predictor of graft function. J
Hepatol. 1999; 30(1):142–8. https://doi.org/10.1016/s0168-8278(99)80018-x PMID: 9927161
PLOS ONE Donor to recipient ICG-PDR variation rate and functional recovery of the liver after transplantation
PLOS ONE | https://doi.org/10.1371/journal.pone.0256786 August 27, 2021 12 / 12
